The popularity of SARMS (Selective Androgenic Receptor Modulators) is reaching new heights with every passing day. The results gained, the ease of cycles, the distinctive appeal and benefits, and the versatility of different SARMS indeed put them in a different league altogether. However, it is important to remember that like every drug, the abuse of SARMS or the absence of qualified knowledge before starting a SARMS cycle can lead to side effects.
Selective Androgenic Receptor Modulators are not known to have side effects as severe as anabolic steroids. SARMS do not aromatize and they are not as toxic as steroids either but it is always better to stay on the safer side than to regret later. Some are of the view that Ostarine (MK-2866) can result in gynecomastia (development of female-like breasts in men) and it is better to stay prepared beforehand. An effective and most typical SARMS cycle support is of 8 weeks and a mini PCT (post cycle therapy) is always recommended after a cycle with SARMS. The best part is that recovery is quick and SARMS users can expect to recover in as less than a week after a mini PCT.
If you are running a GW-501516 (Cardarine) as a standalone cycle, you may not require even the mini PCT. For all other SARMS, a mini PCT is highly recommended. If you want to run LGD-4033, an on-cycle support and PCT (with Clomid and Nolvadex) just like with a traditional steroid cycle is recommended. A mini PCT is also recommended if you want to run S4-Andarine or MK-2866 (Ostraine).
Most SARMS users make use of Ostarine (MK-2866) and GW-501516 (Cardarine) for post cycle therapy. GW501516, a selective agonist (activator) of the peroxisome proliferator-activated receptor-δ (PPARδ) receptor, is a favorite among many. Compounds such as Aromasin or Arimidex can always be added as SARMS cycle support for added protection and prevention.
Visit these site for more info:
- SARMs 101 https://www.isarms.com/selective-androgen-receptor-modulators
- PPARδ https://en.wikipedia.org/wiki/Peroxisome_proliferator-activated_receptor_delta